Cytotoxicity of replication-competent adenoviruses powered by an exogenous regulatory region is not linearly correlated with the viral infectivity/gene expression or with the E1A-activating ability but is associated with the p53 genotypes

[1]  F. Hodi,et al.  Talimogene Laherparepvec for the Treatment of Advanced Melanoma , 2016, Clinical Cancer Research.

[2]  J. Brenton,et al.  Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control , 2015, Molecular oncology.

[3]  S. Kim,et al.  Establishment of a mouse melanoma model system for the efficient infection and replication of human adenovirus type 5-based oncolytic virus. , 2014, Biochemical and biophysical research communications.

[4]  M. Tagawa,et al.  Mesenchymal stem cells are efficiently transduced with adenoviruses bearing type 35-derived fibers and the transduced cells with the IL-28A gene produces cytotoxicity to lung carcinoma cells co-cultured , 2014, BMC Cancer.

[5]  Rong-Fu Chen,et al.  Adenoviruses Types, Cell Receptors and Local Innate Cytokines in Adenovirus Infection , 2014, International reviews of immunology.

[6]  T. Yamano,et al.  Enhanced antitumor efficacy of fiber‐modified, midkine promoter‐regulated oncolytic adenovirus in human malignant mesothelioma , 2013, Cancer science.

[7]  S. Kim,et al.  The effectiveness of the oncolytic activity induced by Ad5/F35 adenoviral vector is dependent on the cumulative cellular conditions of survival and autophagy. , 2013, International journal of oncology.

[8]  Masato Yamamoto,et al.  Generation of a novel, cyclooxygenase-2-targeted, interferon-expressing, conditionally replicative adenovirus for pancreatic cancer therapy. , 2012, American journal of surgery.

[9]  N. Lemoine,et al.  Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  W. Liu,et al.  Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma. , 2011, Cancer letters.

[11]  F. McCormick,et al.  Integrin αvβ5 is a primary receptor for adenovirus in CAR-negative cells , 2010, Virology Journal.

[12]  S. Mittal,et al.  Adenovirus receptors and their implications in gene delivery , 2009, Virus Research.

[13]  M. Tagawa,et al.  Gene medicine for cancer treatment: Commercially available medicine and accumulated clinical data in China , 2008, Drug design, development and therapy.

[14]  P. Sova,et al.  Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting , 2006, Cancer Gene Therapy.

[15]  S. Lupold,et al.  Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  M. Lamfers,et al.  The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. , 2006, Journal of neurosurgery.

[17]  N. Seki,et al.  Increased infectivity of adenovirus type 5 bearing type 11 or type 35 fibers to human esophageal and oral carcinoma cells. , 2005, Oncology reports.

[18]  S. Russell,et al.  High CD46 Receptor Density Determines Preferential Killing of Tumor Cells by Oncolytic Measles Virus , 2004, Cancer Research.

[19]  K. Hamada,et al.  Midkine promoter-driven suicide gene expression and -mediated adenovirus replication produced cytotoxic effects to immortalised and tumour cells. , 2004, European journal of cancer.

[20]  Fengzhi Li,et al.  Induction of Survivin Expression by Taxol (Paclitaxel) Is an Early Event, Which Is Independent of Taxol-mediated G2/M Arrest* , 2004, Journal of Biological Chemistry.

[21]  A. Sagalowsky,et al.  Epigenetic regulation of coxsackie and adenovirus receptor (CAR) gene promoter in urogenital cancer cells. , 2003, Cancer research.

[22]  Y. Shiratori,et al.  Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus. , 2001, Biochemical and biophysical research communications.

[23]  R. Alemany,et al.  Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  A. Nakagawara,et al.  Expression of herpes simplex virus‐thymidine kinase gene controlled by a promoter region of the midkine gene confers selective cytotoxicity to ganciclovir in human carcinoma cells , 2001, International journal of cancer.

[25]  A. Lieber,et al.  Dependence of Adenovirus Infectivity on Length of the Fiber Shaft Domain , 2000, Journal of Virology.

[26]  P. Vliet,et al.  Mechanism of DNA replication in eukaryotic cells: cellular host factors stimulating adenovirus DNA replication. , 1999 .

[27]  A. Fattaey,et al.  An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.

[28]  N. Iizuka,et al.  Cytokine mRNA expression patterns in human esophageal cancer cell lines. , 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[29]  A. Tangoku,et al.  Establishment and Characterization of a New Human Esophageal Cancer Cell Line (YES-2) , 1994 .

[30]  I. McNeish,et al.  p21 promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker , 2009, Molecular Cancer.

[31]  M. Tagawa,et al.  Transcriptional regulatory regions of the survivin gene activate an exogenous suicide gene in human tumors and enhance the sensitivity to a prodrug. , 2007, Anticancer research.

[32]  A. Kyritsis,et al.  p53 enhances the Delta-24 conditionally replicative adenovirus anti-glioma effect. , 2006, Oncology reports.

[33]  G. Vartholomatos,et al.  p53 enhances the Δ-24 conditionally replicative adenovirus anti-glioma effect , 2006 .

[34]  D. Kirn,et al.  A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  H. Shimada,et al.  Promoter-controlled infectivity-enhanced conditionally replicative adenoviral vectors for the treatment of gastric cancer , 2004, Journal of Gastroenterology.

[36]  P. C. van der Vliet,et al.  Mechanism of DNA replication in eukaryotic cells: cellular host factors stimulating adenovirus DNA replication. , 1999, Gene.